Biomarkers during intensive care for sepsis

The article presents the results of a prospective, single-center observational clinical trial, in which biomarker levels were compared in patients with sepsis.

Objective: to evaluate the dynamics of the level of presepsin, procalciotonin and C-reactive protein in two groups - the dead and the surviving patients with sepsis.

Materials and methods. The study consistently included 41 patients with a diagnosis of sepsis (based on the concept of "Sepsis-3"), divided into two groups: group 1 (21 people) – survivors, group 2 (20 people) – dead. Patients in both groups received conventional intensive therapy for sepsis. In addition to the standard laboratory and instrumental examination, patients in the dynamics were monitored for the level of presepsin, procalcitonin, C-reactive protein.

Results. The average level of presepsin in group 1 and group 2 was 1718.00 and 3266.50 pg/ml, respectively, with half of the values being within (Me (25.75) 1021.00–3231.00 and 1618.50–7469.00 pg/ml. The average level of procalcitonin in group 1 and group – 0.995 and 4.465 ng/ml, respectively, while Me (25.75) 0.49–4.44 and 1.625–19.30 ng/ml. The average level of C-reactive protein in group No. 1 and group No. 2 is 95.5 and 215.0 mg/l, respectively, with Me (25.75) 64.00–155.00 and 155.00–264.00 mg/l. When comparing the values of biomarkers in the two groups of patients, significant differences were found (p-value for presepsin, procalсitonina and C-reactive protein are, respectively 0.000008, 0.000242, 0.0000001).

1. Zou Q., Wen W., Zhang X.C.. Presepsin as a novel sepsis biomarker World J Emerg Med. 2014; 5(1): 16–19. https://doi.org/10.5847/wjem.j.issn.1920-8642.2014.01.002

2. Jawad I., Luksic I., Rafnsson S.B. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Global Health. 2012; 2: 1–9. https://doi.org/10.7189/jogh.01.010404

3. Martin G.S. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti-Infect Ther. 2012; 10: 701–6. https://doi.org/10.1586/eri.12.50

4. Singer M., Deutschman C.S., Seymour C.W., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8): 801–810. https://doi.org/10.1001/jama.2016.0287

5. Fan S.L., Miller N.S., Lee J., Remick D.G. Diagnosing sepsis: the role of laboratory medicine. Clin Chim Acta. 2016; 460: 203–210. https://doi.org/10.1016/j.cca.2016.07.002

6. Rhodes A., Evans L.E., Alhazzani W., et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017; 45(3): 486–552 https://doi.org/10.1097/CCM.0000000000002255

7. De Jong E., van Oers J.A., Beishuizen A., et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016; 16: 819–827. https://doi.org/10.1016/S1473-3099(16)00053-0

8. Ali F.T., Ali M.A., Elnakeeb M.M., Bendary H.N.. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta. 2016; 460: 93–101. https://doi.org/10.1016/j.cca.2016.06.030

9. Behnes M., Bertsch T., Lepiorz D., et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014; 18: 507. https://doi.org/10.1186/s13054-014-0507-z

10. Klouche K., Cristol J.P., Devin J., et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care. 2016; 6: 59. https://doi.org/10.1186/s13613-016-0160-6

11. Julian-Jimenez A., Candel-Gonzalez F.J., Gonzalez Del Castillo J. Usefulness of inflammation and infection biomarkers in the Emergency Department. Enferm Infecc Microbiol Clin. 2014; 32(3): 177–190. https://doi.org/10.1016/j.eimc.2013.01.005

12. Cakir Madenci O., Yakupoglu S., Benzonana N., et al. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns. 2014; 40(4): 664–669. https://doi.org/10.1016/j.burns.2013.08.024

13. Carpio R., Zapata J., Spanuth E., Hess G. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department. Clin Chim Acta. 2015; 450: 169–175. https://doi.org/10.1016/j.cca.2015.08.013

14. Endo S., Suzuki Y., Takahashi G., et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012; 18(6): 891–897. https://doi.org/10.1007/s10156-012-0435-2

15. Godnic M., Stubljar D., Skvarc M., Jukic T. Diagnostic and prognostic value of sCD14-ST–presepsin for patients admitted to hospital intensive care unit (ICU) Wien Klin Wochenschr. 2015; 127(13–14): 521– 527. https://doi.org/10.1007/s00508-015-0793-8

16. Ishikura H., Nishida T., Murai A., et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. Crit Care. 2014; 18(1): R19. https://doi.org/10.1186/cc13700

17. Kweon O.J., Choi J.H., Park S.K., Park A.J. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. J Crit Care. 2014; 29(6): 965–970. https://doi.org/10.1016/j.jcrc.2014.06.014

18. Liu B., Chen Y.X., Yin Q., Zhao Y.Z., Li C.S. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care. 2013; 17(5): R244. https://doi.org/10.1186/cc13070

19. Sepsis: classification, clinical diagnostic concept and treatment. Ed. by acad. RAS B.R. Gelfand = Sepsis: klassifikatsiya, kliniko-diagnosticheskaya kontseptsiya i lechenie. Pod redaktsiei akademika RAN B.R. Gel'fanda. Moscow: MIA, 2017. 351 s. (In Russ.)

20. Velkov V.V. Presepsin is a new highly effective biomarker of sepsis = Velkov V.V. Presepsin – new highly effective sepsis biomarker. Kliniko-laboratornyi konsilium. Nauchno-prakticheskii zhurnal. 2012: 2(42): 56–62. (In Russ.)

21. Demidova V.S., Ushakova T.A., Zvyagin A.A., et al. The clinical significance of presepsin in infectious complications in surgical patients and patients with burn injuries = Demidova V.S., Ushakova T.A., Zvyagin A.A. i dr. The clinical significance of presepsine in infectious complications in patients with surgical infection and burn trauma. Infektsii v khirurgii. 2014: 4: 44–46. (In Russ.)

22. Gelfand B.R., Protsenko D.N., Gelfand E.B., Yaroshetsky A.I. Sepsis: pathogenesis and modern methods of intensive therapy = Gel'fand B.R., Protsenko D.N., Gel'fand E.B., Yaroshetskii A.I. Sepsis: patogenez i sovremennye metody intensivnoi terapii. Rukovodstvo po ekstrakorporal'nomu ochishcheniyu krovi v intensivnoi terapii. 2009. S. 273–299 (In Russ.)

23. Gelfand, B.R., Bournevich, S.Z., Gelfand, E.B. et al., Brazhnik, T.B., Sergeeva, N.A. Biochemical markers of systemic inflammatory response: the role of procalcitonin in the diagnosis of sepsis = Gel'fand B.R., Burnevich S.Z., Gel'fand Ye.B. i dr. Biokhimicheskiye markery sistemnoy vospalitel'noy reaktsii: rol' prokal'tsitonina v diagnostike sepsisa. Infektsiya v khirurgii. 2007; 5(1): 17–24. (In Russ.)

24. Velkov V.V. Procalcitonin and c-reactive protein in modern laboratory diagnostics. Part 2 = Prokal'tsitonin i s-reaktivnyy belok v sovremennoy laboratornoy diagnostike. Chast' 2. Kliniko-laboratornyi konsilium, Nauchno-prakticheskii zhurnal. 2009; 1(26): 34–48. (In Russ.)

25. Vodnik T., Kaljevic G., Tadic T., Majkic-Singh N. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clin Chem Lab Med. 2013; 51: 2053– 2062. https://doi.org/10.1515/cclm-2013-0061